Last 12 months
Inside the activity.
0 purchase rows · 5 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2019 Filed Jun 11, 2019 01:18 UTC |
KANOVSKY STEPHEN MDirector
|
GrantStock Options (Right to Buy) · Derivative | 4,269 | $0.00 Strike: $22.52 | $0.00 |
DisclosureSEC source: 0001077183-19-000111 · wf-form4_156021586726965.xml · derivative · entry 2 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,269 Underlying: Common Stock · 4,269 shares Expires 2026-06-06 Read SEC document |
| June 06, 2019 Filed Jun 11, 2019 01:18 UTC |
KANOVSKY STEPHEN MDirector
|
GrantCommon Stock | 3,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000111 · wf-form4_156021586726965.xml · nonDerivative · entry 1 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,419 Read SEC document |
| June 06, 2019 Filed Jun 11, 2019 01:17 UTC |
Johnson Kevin CDirector
|
GrantStock Option (Right to Buy) · Derivative | 4,269 | $0.00 Strike: $22.52 | $0.00 |
DisclosureSEC source: 0001077183-19-000110 · wf-form4_156021582989165.xml · derivative · entry 6 Johnson Kevin C · CIK 0001353436 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,269 Underlying: Common Stock · 4,269 shares Expires 2026-06-06 Read SEC document |
| June 06, 2019 Filed Jun 11, 2019 01:17 UTC |
Johnson Kevin CDirector
|
GrantCommon Stock | 3,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000110 · wf-form4_156021582989165.xml · nonDerivative · entry 1 Johnson Kevin C · CIK 0001353436 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,285 Read SEC document |
| June 06, 2019 Filed Jun 11, 2019 01:16 UTC |
CROWTHER BRUCE KDirector
|
GrantStock Options (Right to Buy) · Derivative | 4,269 | $0.00 Strike: $22.52 | $0.00 |
DisclosureSEC source: 0001077183-19-000109 · wf-form4_156021577116075.xml · derivative · entry 6 CROWTHER BRUCE K · CIK 0001244274 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,269 Underlying: Common Stock · 4,269 shares Expires 2026-06-06 Read SEC document |
| June 06, 2019 Filed Jun 11, 2019 01:16 UTC |
CROWTHER BRUCE KDirector
|
GrantCommon Stock | 3,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000109 · wf-form4_156021577116075.xml · nonDerivative · entry 1 CROWTHER BRUCE K · CIK 0001244274 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,185 Read SEC document |
| June 06, 2019 Filed Jun 11, 2019 01:15 UTC |
HANNAH ALISON L.Director
|
GrantStock Options (Right to Buy) · Derivative | 4,269 | $0.00 Strike: $22.52 | $0.00 |
DisclosureSEC source: 0001077183-19-000108 · wf-form4_156021573544544.xml · derivative · entry 6 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,269 Underlying: Common Stock · 4,269 shares Expires 2026-06-06 Read SEC document |
| June 06, 2019 Filed Jun 11, 2019 01:15 UTC |
HANNAH ALISON L.Director
|
GrantCommon Stock | 3,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000108 · wf-form4_156021573544544.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,432 Read SEC document |
| June 06, 2019 Filed Jun 11, 2019 01:14 UTC |
HIPP RAYMOND RDirector
|
GrantStock Option (Right to Buy) · Derivative | 4,269 | $0.00 Strike: $22.52 | $0.00 |
DisclosureSEC source: 0001077183-19-000107 · wf-form4_156021567984441.xml · derivative · entry 5 HIPP RAYMOND R · CIK 0001188214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,269 Underlying: Common Stock · 4,269 shares Expires 2026-06-06 Read SEC document |
| June 06, 2019 Filed Jun 11, 2019 01:14 UTC |
HIPP RAYMOND RDirector
|
GrantCommon Stock | 3,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000107 · wf-form4_156021567984441.xml · nonDerivative · entry 1 HIPP RAYMOND R · CIK 0001188214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,999 Read SEC document |
| June 06, 2019 Filed Jun 11, 2019 01:13 UTC |
JONES STEVEN CDirector
|
GrantStock Option (Right to Buy) · Derivative | 4,269 | $0.00 Strike: $22.52 | $0.00 |
DisclosureSEC source: 0001077183-19-000106 · wf-form4_156021561175678.xml · derivative · entry 10 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,269 Underlying: Common Stock · 4,269 shares Expires 2026-06-06 Read SEC document |
| June 06, 2019 Filed Jun 11, 2019 01:13 UTC |
JONES STEVEN CDirector
|
GrantCommon Stock | 3,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000106 · wf-form4_156021561175678.xml · nonDerivative · entry 4 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,234 Read SEC document |
| May 25, 2019 Filed May 30, 2019 00:50 UTC |
VAN OORT DOUGLAS MDirector · Chairman and CEO
|
Tax withholdingCommon Stock | 25,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000097 · wf-form4_155917738612994.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,066,589 F2 · shares: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the May 25, 2019 vesting of restricted stock. Read SEC document |
| May 25, 2019 Filed May 30, 2019 00:51 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
Tax withholdingCommon Stock | 6,559 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000098 · wf-form4_155917744753839.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,748 F1 · shares: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the May 25, 2019 vesting of restricted stock. Read SEC document |
| May 08, 2019 Filed May 10, 2019 01:55 UTC |
HIPP RAYMOND RDirector
|
SaleCommon Stock | 118,479 | $22.36 | $2,649,190.44 |
DisclosureSEC source: 0001077183-19-000070 · wf-form4_155745332576193.xml · nonDerivative · entry 2 HIPP RAYMOND R · CIK 0001188214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,580 Read SEC document |
| May 07, 2019 Filed May 10, 2019 01:55 UTC |
HIPP RAYMOND RDirector
|
SaleCommon Stock | 31,521 | $22.61 | $712,689.81 |
DisclosureSEC source: 0001077183-19-000070 · wf-form4_155745332576193.xml · nonDerivative · entry 1 HIPP RAYMOND R · CIK 0001188214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,059 Read SEC document |
| May 06, 2019 Filed May 8, 2019 21:02 UTC |
Bonello WilliamChief Strategy Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,200 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0001077183-19-000068 · wf-form4_155734933349567.xml · derivative · entry 3 Bonello William · CIK 0001454941 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,763 Underlying: Common Stock · 79,963 shares Expires 2022-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 28, 2017, Mr. Bonello was granted an option to purchase shares of NeoGenomics, Inc. common stock. The options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| May 06, 2019 Filed May 8, 2019 21:02 UTC |
Bonello WilliamChief Strategy Officer
|
SaleCommon Stock | 7,200 | $23.53 | $169,416.00 |
DisclosureSEC source: 0001077183-19-000068 · wf-form4_155734933349567.xml · nonDerivative · entry 2 Bonello William · CIK 0001454941 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,735 Read SEC document |
| May 06, 2019 Filed May 8, 2019 21:02 UTC |
Bonello WilliamChief Strategy Officer
|
Exercise / conversionCommon Stock | 7,200 | $7.52 | $54,144.00 |
DisclosureSEC source: 0001077183-19-000068 · wf-form4_155734933349567.xml · nonDerivative · entry 1 Bonello William · CIK 0001454941 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2019 Filed May 6, 2019 21:33 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
SaleCommon Stock | 13,333 | $22.74 | $303,192.42 |
DisclosureSEC source: 0001077183-19-000059 · wf-form4_155717836502995.xml · nonDerivative · entry 4 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,862 Read SEC document |
| May 03, 2019 Filed May 6, 2019 21:33 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
SaleCommon Stock | 16,667 | $22.74 | $379,007.58 |
DisclosureSEC source: 0001077183-19-000059 · wf-form4_155717836502995.xml · nonDerivative · entry 3 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,195 Read SEC document |
| May 03, 2019 Filed May 6, 2019 21:30 UTC |
CARDOZA GEORGEPresident, Pharma Services
|
SaleCommon Stock | 151,676 | $22.82 | $3,461,246.32 |
DisclosureSEC source: 0001077183-19-000057 · wf-form4_155717822198878.xml · nonDerivative · entry 3 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,831 Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:31 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 66,667 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0001077183-19-000058 · wf-form4_155717829283180.xml · derivative · entry 7 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 66,667 shares Expires 2022-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On April 28, 2017, Mr. Shovlin was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:31 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 66,666 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001077183-19-000058 · wf-form4_155717829283180.xml · derivative · entry 5 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,666 shares Expires 2021-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 20, 2016, Mr. Shovlin was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:31 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
SaleCommon Stock | 66,667 | $22.14 | $1,476,007.38 |
DisclosureSEC source: 0001077183-19-000058 · wf-form4_155717829283180.xml · nonDerivative · entry 4 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,307 Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:31 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
SaleCommon Stock | 52,680 | $22.14 | $1,166,335.20 |
DisclosureSEC source: 0001077183-19-000058 · wf-form4_155717829283180.xml · nonDerivative · entry 3 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,974 Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:31 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
Exercise / conversionCommon Stock | 66,667 | $7.52 | $501,335.84 |
DisclosureSEC source: 0001077183-19-000058 · wf-form4_155717829283180.xml · nonDerivative · entry 2 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:31 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
Exercise / conversionCommon Stock | 66,666 | $7.15 | $476,661.90 |
DisclosureSEC source: 0001077183-19-000058 · wf-form4_155717829283180.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:33 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 13,333 | $7.52 Strike: $7.52 | $100,264.16 |
DisclosureSEC source: 0001077183-19-000059 · wf-form4_155717836502995.xml · derivative · entry 8 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,667 Underlying: Common Stock · 13,333 shares Expires 2022-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On April 28, 2017, Jennifer Balliet was granted 60,000 stock options. The options vest ratably over the first three anniversaries of the grant date. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:33 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 16,667 | $7.15 Strike: $7.15 | $119,169.05 |
DisclosureSEC source: 0001077183-19-000059 · wf-form4_155717836502995.xml · derivative · entry 5 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires 2021-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 20, 2016, Jennifer Balliet was granted 50,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:33 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionCommon Stock | 13,333 | $7.52 | $100,264.16 |
DisclosureSEC source: 0001077183-19-000059 · wf-form4_155717836502995.xml · nonDerivative · entry 2 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:33 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionCommon Stock | 16,667 | $7.15 | $119,169.05 |
DisclosureSEC source: 0001077183-19-000059 · wf-form4_155717836502995.xml · nonDerivative · entry 1 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:30 UTC |
CARDOZA GEORGEPresident, Pharma Services
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $4.78 | $0.00 |
DisclosureSEC source: 0001077183-19-000057 · wf-form4_155717822198878.xml · derivative · entry 4 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2020-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On May 4, 2015 Mr. Cardoza was granted an option to purchase 200,000 shares. These options vest ratably over the first three anniversary dates of the grant. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:30 UTC |
CARDOZA GEORGEPresident, Pharma Services
|
Exercise / conversionCommon Stock | 200,000 | $4.78 | $956,000.00 |
DisclosureSEC source: 0001077183-19-000057 · wf-form4_155717822198878.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2019 Filed Mar 4, 2019 22:25 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $8.03 | $0.00 |
DisclosureSEC source: 0001077183-19-000020 · wf-form4_155173830561711.xml · derivative · entry 10 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,500 Underlying: Common Stock · 14,000 shares Expires 2023-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On February 26, 2018, Jennifer Balliet was granted 72,500 stock options which vested ratably over the first three anniversary dates of the grant date. Read SEC document |
| March 04, 2019 Filed Mar 4, 2019 22:25 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
SaleCommon Stock | 14,000 | $19.09 | $267,260.00 |
DisclosureSEC source: 0001077183-19-000020 · wf-form4_155173830561711.xml · nonDerivative · entry 6 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,862 F1 · price: Average price of shares sold. Read SEC document |
| March 04, 2019 Filed Mar 4, 2019 22:25 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionCommon Stock | 14,000 | $8.03 | $112,420.00 |
DisclosureSEC source: 0001077183-19-000020 · wf-form4_155173830561711.xml · nonDerivative · entry 5 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:25 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
GrantStock Option (Right to Buy) · Derivative | 17,496 | $19.60 Strike: $19.60 | $342,921.60 |
DisclosureSEC source: 0001077183-19-000020 · wf-form4_155173830561711.xml · derivative · entry 9 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,496 Underlying: Common Stock · 17,496 shares Expires 2024-03-01 F4 · derivative.exercise_date: On March 1, 2019, Ms. Balliet was granted 17,496 stock options which vested ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:25 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
GrantCommon Stock | 2,862 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000020 · wf-form4_155173830561711.xml · nonDerivative · entry 4 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,862 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:10 UTC |
VAN OORT DOUGLAS MDirector · Chairman and CEO
|
GrantStock Option (Right to Buy) · Derivative | 231,567 | $19.60 Strike: $19.60 | $4,538,713.20 |
DisclosureSEC source: 0001077183-19-000037 · wf-form4_155182381624439.xml · derivative · entry 3 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,567 Underlying: Common Stock · 231,567 shares Expires 2024-03-01 F2 · derivative.exercise_date: On March 1, 2019, Mr. VanOort was granted an option to purchase 231,567 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:10 UTC |
VAN OORT DOUGLAS MDirector · Chairman and CEO
|
GrantCommon Stock | 37,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000037 · wf-form4_155182381624439.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,092,435 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:07 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
GrantStock Option (Right to Buy) · Derivative | 66,897 | $19.60 Strike: $19.60 | $1,311,181.20 |
DisclosureSEC source: 0001077183-19-000035 · wf-form4_155182364657501.xml · derivative · entry 2 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,897 Underlying: Common Stock · 66,897 shares Expires 2024-03-01 F1 · derivative.exercise_date: On March 1, 2019, Mr. Shovlin was granted an option to purchase 66,897 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:07 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
GrantCommon Stock | 10,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000035 · wf-form4_155182364657501.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,321 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:05 UTC |
Virag SharonChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 66,897 | $19.60 Strike: $19.60 | $1,311,181.20 |
DisclosureSEC source: 0001077183-19-000033 · wf-form4_155182350627886.xml · derivative · entry 2 Virag Sharon · CIK 0001576811 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,897 Underlying: Common Stock · 66,897 shares Expires 2024-03-01 F1 · derivative.exercise_date: On March 1, 2019, Ms. Virag was granted an option to purchase shares of NeoGenomics, Inc. common stock. The option vests ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:05 UTC |
Virag SharonChief Financial Officer
|
GrantCommon Stock | 10,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000033 · wf-form4_155182350627886.xml · nonDerivative · entry 1 Virag Sharon · CIK 0001576811 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,944 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:01 UTC |
CARDOZA GEORGEPresident, Pharma Services
|
GrantStock Option (Right to Buy) · Derivative | 51,459 | $19.60 Strike: $19.60 | $1,008,596.40 |
DisclosureSEC source: 0001077183-19-000031 · wf-form4_155182329877820.xml · derivative · entry 3 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,459 Underlying: Common Stock · 51,459 shares Expires 2024-03-01 F1 · derivative.exercise_date: On March 1, 2019 Mr. Cardoza was granted an option to purchase 51,459 shares. These options vest ratably over the first four anniversary dates of the grant. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:01 UTC |
CARDOZA GEORGEPresident, Pharma Services
|
GrantCommon Stock | 8,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000031 · wf-form4_155182329877820.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,507 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:59 UTC |
McKenzie Kathryn BPrincipal Accounting Officer
|
GrantStock Option (Right to Buy) · Derivative | 13,894 | $19.60 Strike: $19.60 | $272,322.40 |
DisclosureSEC source: 0001077183-19-000029 · wf-form4_155182313355816.xml · derivative · entry 2 McKenzie Kathryn B · CIK 0001720001 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,894 Underlying: Common Stock · 13,894 shares Expires 2024-03-01 F1 · derivative.exercise_date: On March 1, 2019, Ms. McKenzie was granted an option to purchase 13,894 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:59 UTC |
McKenzie Kathryn BPrincipal Accounting Officer
|
GrantCommon Stock | 2,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000029 · wf-form4_155182313355816.xml · nonDerivative · entry 1 McKenzie Kathryn B · CIK 0001720001 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,273 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:53 UTC |
Bonello WilliamChief Strategy Officer
|
GrantStock Option (Right to Buy) · Derivative | 41,167 | $19.60 Strike: $19.60 | $806,873.20 |
DisclosureSEC source: 0001077183-19-000027 · wf-form4_155182281921308.xml · derivative · entry 2 Bonello William · CIK 0001454941 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,167 Underlying: Common Stock · 41,167 shares Expires 2024-03-01 F1 · derivative.expiration_date: On March 1, 2019, Mr. Bonello was granted an option to purchase shares of NeoGenomics, Inc. common stock. The options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.